Login / Signup

Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.

C GuYuemeng WuY LuoS WangH YinY GaoC WangX YaoWei Li
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Dupilumab demonstrated favourable efficacy and well-tolerated safety in Chinese AD patients in real-world practice.
Keyphrases
  • atopic dermatitis
  • open label
  • end stage renal disease
  • newly diagnosed
  • healthcare
  • clinical trial
  • chronic kidney disease
  • primary care
  • peritoneal dialysis
  • prognostic factors
  • study protocol